A Phase III Study in Subjects With Mild to Moderate Psoriasis.

Condition:   Mild to Moderate Psoriasis Interventions:   Drug: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO);   Drug: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g);   Other: Placebo Sponsor:   Lipidor AB Recruiting

Source: ClinicalTrials.gov - February 22, 2022 Category: Research Source Type: clinical trials